Novel agents targeting the JAK/STAT and related pathways, such as ND-16, ECPIRM, tyrphostin AG490, cucurbitacin, and pimozide, have shown efficacy in preclinical studies and represent exciting future directions for CTCL therapy. Here, SOAT1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.